cilomilast has been researched along with Palmoplantaris Pustulosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, W; Dong, G; Feng, C; Gu, Z; Li, H; Li, J; Li, M; Liu, H; Tang, W; Xu, Y; Zhang, R; Zhang, X; Zhu, F | 1 |
| Alalaiwe, A; Elzoghby, AO; Fang, JY; Hsu, CY; Hwang, TL; Lin, CY | 1 |
2 other study(ies) available for cilomilast and Palmoplantaris Pustulosis
| Article | Year |
|---|---|
Structure-Aided Identification and Optimization of Tetrahydro-isoquinolines as Novel PDE4 Inhibitors Leading to Discovery of an Effective Antipsoriasis Agent.
Topics: Animals; Caco-2 Cells; Catalytic Domain; Cyclic Nucleotide Phosphodiesterases, Type 4; Drug Design; Drug Evaluation, Preclinical; Female; HEK293 Cells; Humans; Male; Mice; Models, Molecular; Phosphodiesterase 4 Inhibitors; Psoriasis; Rats; Stereoisomerism; Structure-Activity Relationship; Tetrahydroisoquinolines; Tissue Distribution | 2019 |
Oleic acid as the active agent and lipid matrix in cilomilast-loaded nanocarriers to assist PDE4 inhibition of activated neutrophils for mitigating psoriasis-like lesions.
Topics: Animals; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Disease Models, Animal; Drug Carriers; Humans; Mice; Mice, Inbred BALB C; Nanoparticles; Neutrophil Activation; Neutrophils; Nitriles; Oleic Acid; Phosphodiesterase 4 Inhibitors; Psoriasis | 2019 |